tiprankstipranks
Trending News
More News >

Taysha Gene Therapies price target raised to $11 from $9 at Canaccord

Canaccord raised the firm’s price target on Taysha Gene Therapies (TSHA) to $11 from $9 and keeps a Buy rating on the shares. The firm noted the company shared both a regulatory and a clinical update (longer term low-dose follow-up data and first look at high-dose data) for its TSHA-102 program for Rett Syndrome. Canaccord updated its model for the updates, namely increasing their assigned POS on TSHA-102 to 75% from 50% previously and the roughly $200M offering via a mix of shares and prefunded warrants.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue